TYMS
Thymidylate synthase
As of the edition of 20 October 2026, TYMS (thymidylate synthase, UniProt P04818) has 13 drugs tested at it and 30 companies on the list, 6 on route A and 7 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P04818
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 61
- Disease areas
- Cancer; Digestive system; Lungs and airways; Skin and connective tissue; Hormones; Urinary and reproductive; Pregnancy and women's health; Mouth and teeth
- Registered trials of its drugs
- 4,211
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Went quiet | 6 |
| Stopped | 1 |
| Total | 13 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Fluorouracil | Marketed | Phase 4 | none listed |
| Capecitabine | Marketed | Phase 4 | none listed |
| Pemetrexed | Marketed | Phase 4 | none listed |
| Tegafur | Marketed | Phase 4 | none listed |
| Floxuridine | Marketed | Phase 3 | none listed |
| Raltitrexed | Marketed | Phase 4 | none listed |
| OSI-7904 | Went quiet | Phase 2 | none listed |
| Fosifloxuridine nafalbenamide | Stopped | Phase 2 | none listed |
| Doxifluridine | Went quiet | Phase 4 | none listed |
| Idetrexed | Went quiet | Phase 1 | none listed |
| NB1011 | Went quiet | Phase 2 | none listed |
| Nolatrexed | Went quiet | Phase 3 | none listed |
12 of 13 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 6 |
| Route B | 7 |
| Engaged | 17 |
| Total on the list | 30 |
| Company | Route |
|---|---|
| Eli Lilly | Route B |
| NuCana | Route A |
| AstraZeneca | Route A |
The other 27 companies at TYMS
In the product30 companies in all; 27 are not named here, and no score is.
See the 30 companies at TYMS, ranked, with the facts behind eachRequest access. Nothing is shown until you do.